ALK-Abello raises 2026 revenue outlook after Q2 organic sales growth of 18%

ALK-Abello, a Danish allergy immunotherapy company, has raised its 2026 revenue outlook after reporting an 18% increase in second-quarter organic sales. The company's Q2 revenue grew to 1.80 billion Danish crowns, up from 1.527 billion crowns in the same period last year, driven by strong sales in its tablets and anaphylaxis products.

Operating profit rose by 19% to 445 million crowns, with an EBIT margin remaining steady at 25%. The company's gross margin improvements were offset by strategic investments, primarily in sales and marketing. Tablet sales grew by 22% to 1.01 billion crowns, with notable contributions from Europe (27%) and North America (17%). Sales of SCIT/SLIT products dropped by 7% to 515 million crowns, mainly due to sales in China.

Anaphylaxis and other product sales rose by 26% to 267 million crowns, largely boosted by the Jext product. Free cash flow in the quarter was 218 million crowns, while capital expenditure decreased to 71 million crowns. The company's full-year revenue growth outlook has been revised to 14%-16%, reflecting the strong momentum in tablet sales and reduced risks associated with price and rebate adjustments in 2026.

The company plans to continue developing its peanut tablet in phase 3 trials, expected to launch in late 2026, and has recently launched its neffy nasal adrenaline spray in Canada and five additional European markets. In the UK, pediatric use of ACARIZAX and ITULAZAX has been recommended for public healthcare reimbursement. CEO Peter Halling attributes the company's double-digit growth in Q2 to its robust strategy, with the pediatric roll-out driving tablet growth and the launch of neffy.